Promising Clinical Results for Inhibrx's Ozekibart in Ewing Sarcoma Treatment

Inhibrx's Revolutionary Advances in Ewing Sarcoma Treatment



Inhibrx Biosciences, a biopharmaceutical company working on innovative therapies, recently presented compelling clinical data for its investigational drug, Ozekibart (INBRX-109), in the treatment of Ewing sarcoma. This rare and aggressive type of cancer predominantly affects children and young adults, making the advancement of effective treatment options crucial. The updated results come from an expansion study of a combined therapy regimen involving Ozekibart and two established chemotherapy agents: irinotecan and temozolomide.

Key Findings from Clinical Trials


As of the latest data cutoff on September 18, 2026, a total of 60 patients—including 9 adolescents—were enrolled in this pivotal study, with 22 patients still undergoing active treatment. Among the 51 evaluable patients:
  • - Overall Response Rate (ORR): An impressive 62.7%, reflecting a mix of complete (2 cases) and partial responses (30 cases).
  • - Disease Control Rate (DCR): High at 86.3%, which includes instances of stable disease.
  • - A notable 84.3% of responders exhibited a measurable decrease in tumor size from initial assessments.

These findings are groundbreaking, especially considering the historical benchmarks for this population, where previous treatments like irinotecan and temozolomide yielded modest ORR rates of roughly 15% to 30% and median progression-free survival durations of only 3 to 4 months. This indicates a significant improvement with Ozekibart's combination therapy.

Longevity of Response


Further examination reveals that 18 patients displayed durable clinical benefits lasting over six months, which is particularly encouraging. Among them, one individual has reportedly maintained a partial response for more than two years—a beacon of hope for similarly diagnosed individuals. Additionally, at the cutoff point, 14 evaluable patients were progression-free, with two of those experiencing durations exceeding 12 months.

Safety Profile of Ozekibart


The safety profile of Ozekibart, when combined with irinotecan and temozolomide, remained largely acceptable and manageable. There were no unexpected cumulative hepatotoxicity events, aligning with known side effects of the individual agents used.

The Need for Innovation


With approximately 300 new Ewing sarcoma cases diagnosed annually in the U.S., and an estimated 2,500 individuals living with the condition, the call for innovative and effective treatment options is critical. The results of this study are not only promising but highlight INHBRX's commitment to advancing care in this underserved community. CEO Mark Lappe emphasized the importance of bringing Ozekibart to patients as soon as possible, based on these compelling results.

Next Steps


In light of the positive data, Inhibrx is rapidly progressing towards submitting a Biologics License Application (BLA) for Ozekibart, which holds the potential to be utilized for patients diagnosed with conventional chondrosarcoma, in addition to its application for Ewing sarcoma. The data from this study will be showcased at the upcoming Connective Tissue Oncology Society (CTOS) 2026 Annual Meeting, further raising awareness about the potential for Ozekibart as a transformative treatment option.

In summary, as Inhibrx continues to develop therapies targeting complex diseases, the commitment to patient care and clinical excellence shines through with the promising results of Ozekibart. As we await additional data and potential approvals, the hope for innovative treatments in Ewing sarcoma remains bright.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.